Global Cell Line Development Market Size, Share, Opportunities, And Trends By Type (Recombinant Cell Lines, Hybridomas, Continuous Cell Lines, Primary Cell Lines), By Source (Mammalian Cell Line Development, Non Mammalian Cell Line Development), By Application (Drug Discovery, Research, Others), And By Geography - Forecasts From 2024 To 2029

The global cell line development market is projected to grow at a CAGR of 13.43% during the forecast period to reach US$8.076 billion by 2029, from US$3.343 billion in 2022.

A cell line is a permanently established cell culture that will proliferate indefinitely given appropriate fresh medium and space and is often used in place of primary cells to study biological processes. Cell line development refers to the process of developing stable cell lines for use in several important applications, including biologics (recombinant protein and monoclonal antibody) production, drug screening, and gene functional studies. The process of cell line development includes transfection and selection and single-cell cloning. Further, the global cell line development market is segmented into type, source, and geography.  

Cell line development is a critical process in pharmaceutical research, biotechnology, and drug development. Key players in the market include companies specializing in cell line development services, equipment, and related technologies. Growth drivers include increasing demand for biopharmaceuticals, R&D investments, and technological advancements. The market is segmented based on product type, source, application, and end-user. Key regions include North America, Europe, and Asia-Pacific. Restraints include regulatory compliance, costs, and time constraints. Future trends include single-use technologies for flexibility and cost-effectiveness and growing interest in continuous manufacturing as an alternative to traditional batch processes. The market is influenced by regional presence, particularly in North America and Europe.

Market Drivers:

• A rise in development and demand for monoclonal antibodies is anticipated to surge the market growth.

The global cell line development market growth is attributed to the rise in development and demand for monoclonal antibodies around the globe. The cell line development market will grow due to the rising demand for cell-based vaccines. The growing number of new virus outbreaks, such as influenza, monkeypox, Ebola, and COVID-19, among others, are contributing to the growing demand for cell-based vaccines. For instance, the World Health Organization’s Disease Outbreak News (DONs), which provided confirmed acute public health events of potential events of concern, reported the first case of the Ebola virus in April 2022.

Additionally, The Ministry of Health of the Democratic Republic of the Congo declared the outbreak of the Ebola virus following a confirmed laboratory test of a 31-year-old male in the North-western Equateur province. Furthermore, Uganda also witnessed a confirmed 18 cases as of 25th September 2022 of the Ebola virus, which was caused by the Sudan Virus. Such increasing cases of infectious diseases and the growing risk of pandemics are the prime factors driving the demand for vaccines worldwide.

Moreover, in June 2022, just after a few months of recovery from the disruptions of the COVID-19 pandemic, the outbreak of monkeypox in different countries alarmed the vaccine developer companies to take measures to control the spread of the new virus. Furthermore, many organizations are putting efforts into developing vaccines for the rising disease. For instance, the Centers for Disease Control and Prevention (CDC) mentions in its Vaccine Considerations Summary updated in September 2022, that the JYNNEOS vaccine is approved for the prevention of monkeypox and smallpox diseases.

Further, the ACAM2000 Vaccines has been approved for immunization against smallpox which is made available for use against monkeypox under Expanded Access Investigational New Drug protocol, mentions the CDC.  As a result, the demand for vaccines is increasing globally, consequently increasing the demand for global cell line developments in the market and supporting the Global cell line development market growth during the anticipated period. 

North American region is expected to hold a significant market share.

 In the global cell line development market, the North American region is expected to hold a significant share during the forecast period. Rising research and development activities, coupled with increasing investment in advanced processes and adoption of cell-based research in countries like the US, are driving the market in this region.

Furthermore, the use of cell lines for biologics production, gene functional studies, and drug screening has further augmented the market’s growth in the North American region. Moreover, the continuous work on vaccine development by the operating pharmaceutical companies and their ambitious plans to expand their geographic reach is anticipated to fuel market expansion in this region.

Key Developments:

• January 2023- Berkeley Lights introduced the Beacon Select™ optofluidic system for cell line development (CLD), allowing scientists to clone, culture, assay, and select top clones in a single run on a single platform. This two-chip, single-cell optofluidic system uses the Opto® CLD workflow, enabling high throughput cloning, screening, and selection of top-performing CHO cell lines in just days. The system can select clones with higher titers, increase throughput by 2x, reduce cell line development timelines by up to 50%, and achieve cloning efficiencies 5x greater than FACS and 10x greater than limiting dilution.
• November 2023- Lonza introduced Capsugel® Enprotect™, the first coating-free capsule for intestinal drug delivery. This coating-free capsule does not disintegrate during stomach transit and only releases its contents in the intestine, simplifying manufacturing and accelerating drug development. Lonza's Capsules & Health Ingredients Division has been a trusted partner for global pharmaceutical and nutraceutical companies. The capsule targets small molecules, peptides, proteins, and RNA-based therapeutics and enables live biotherapeutic product delivery.
• October 2022- Lonza, a global manufacturing partner for the pharma, biotech, and nutrition industries, expanded its cell and gene therapies (CGT) process and analytical development laboratories at its Houston and Geleen facilities. The expansions add 15,000 square feet of new lab suites in Houston, including viral vector-based laboratories, and 4,500 square feet in Geleen, Netherlands.
• April 2022- Applied Cells and STEMCELL Technologies partnered to develop a high-performance cell separation solution that combines Applied Cells' MARS® platform with STEMCELL's EasySep™ immunomagnetic cell separation kits. The goal is to automate and increase efficiency in isolating high-quality cells from various sample types, such as whole blood, bone marrow, apheresis products, and dissociated tissue. The MARS platform uses a "multi-physics" approach for efficient sample preparation and isolation, while STEMCELL's EasySep™ technology enables fast and easy cell isolation.

Company Products:

• CHO-M Selexis SURE Technology- KBI Biopharma offers mammalian cell line development and can create mammalian protein expression systems by using cell line generation services like CHO-M Selexis SURE Technology. Furthermore, the company makes available both transient expression and stable pool generation approaches to aid proof-of-concept material generation for preclinical programs.
• Range of mammalian cell lines- Fusion Antibodies Plc. can deliver a range of mammalian cell lines to offer confidence and flexibility in supporting the users’ clinical development. The company claims that it can cater to the requirement of rapid development of well-characterized mammalian cell lines with good clinical records. 

Market Segments:

• By Type
  • Recombinant Cell Lines
  • Hybridomas
  • Continuous Cell Lines
  • Primary Cell Lines
• By Source
  • Mammalian Cell Line Development
  • Non-Mammalian Cell Line Development 
• By Application
  • Drug discovery
  • Research
  • Others
• By Geography
  • North America
    • USA
    • Canada
    • México
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • Israel
    • Others
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Indonesia
    • Others